Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
Pfizer has announced the US Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the […]
LivaNova Receives FDA Clearance for Essenz Heart-Lung Machine for Cardiopulmonary Bypass Procedures
LivaNova, a market-leading medical technology and innovation company, today announced it received United States Food […]
FDA Accepts Supplemental New Drug Application for Jardiance® for Children 10 years and Older with Type 2 Diabetes
The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for […]
BioMarin Provides Update on FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A
BioMarin Pharmaceutical, a global biotechnology company dedicated to transforming lives through genetic discovery, today announced […]
Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
Cantex Pharmaceuticals, a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other […]
FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma
Aldeyra Therapeutics has announced that the US Food and Drug Administration (FDA) accepted for Priority […]
Sooma Medical Receives FDA Breakthrough Device Designation for Its Innovative At-Home Depression Treatment Device
Sooma Medical, a medical device company based in Finland, has been granted Breakthrough Device designation […]
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Eisai and Biogen announced today that the US Food and Drug Administration (FDA) has accepted […]
Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia
Reata Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing novel therapies for patients with […]
Pfizer Receives Potential FDA Approval for RSV Vaccine Candidate
Pfizer has announced that the US Food and Drug Administration’s (FDA) Vaccines and Related Biological […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more